841 related articles for article (PubMed ID: 18707763)
1. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
Gagliotti C; Buttazzi R; Sforza S; Moro ML;
J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
[TBL] [Abstract][Full Text] [Related]
4. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition.
Smith SP; Manges AR; Riley LW
Clin Infect Dis; 2008 Mar; 46(5):689-95. PubMed ID: 18230040
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection.
Killgore KM; March KL; Guglielmo BJ
Ann Pharmacother; 2004; 38(7-8):1148-52. PubMed ID: 15150380
[TBL] [Abstract][Full Text] [Related]
6. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain.
Gobernado M; Valdés L; Alós JI; García-Rey C; Dal-Ré R; García-de-Lomas J;
Rev Esp Quimioter; 2007 Mar; 20(1):68-76. PubMed ID: 17530038
[TBL] [Abstract][Full Text] [Related]
8. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
[TBL] [Abstract][Full Text] [Related]
9. Anti-microbial resistance stratified by risk factor among Escherichia coli strains isolated from the urinary tract at a rural clinic in Central India.
Chatterjee B; Kulathinal S; Bhargava A; Jain Y; Kataria R
Indian J Med Microbiol; 2009; 27(4):329-34. PubMed ID: 19736402
[TBL] [Abstract][Full Text] [Related]
10. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of catheter-associated urinary tract infections and multi-drug-resistant Escherichia coli isolates from the urine of dogs with indwelling urinary catheters.
Ogeer-Gyles J; Mathews K; Weese JS; Prescott JF; Boerlin P
J Am Vet Med Assoc; 2006 Nov; 229(10):1584-90. PubMed ID: 17107313
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
[TBL] [Abstract][Full Text] [Related]
13. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples.
Gagliotti C; Nobilio L; Moro ML;
Clin Microbiol Infect; 2007 Mar; 13(3):328-31. PubMed ID: 17391392
[TBL] [Abstract][Full Text] [Related]
14. [E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
Talon D; Lallemand-De-Conto S; Thouverez M; Bertrand X
Pathol Biol (Paris); 2004 Mar; 52(2):76-81. PubMed ID: 15001235
[TBL] [Abstract][Full Text] [Related]
15. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines.
Bours PH; Polak R; Hoepelman AI; Delgado E; Jarquin A; Matute AJ
Int J Infect Dis; 2010 Sep; 14(9):e770-4. PubMed ID: 20637675
[TBL] [Abstract][Full Text] [Related]
16. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli.
Ejrnæs K
Dan Med Bull; 2011 Apr; 58(4):B4187. PubMed ID: 21466767
[TBL] [Abstract][Full Text] [Related]
17. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.
Urbánek K; Kolár M; Strojil J; Koukalová D; Cekanová L; Hejnar P
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):741-5. PubMed ID: 15880441
[TBL] [Abstract][Full Text] [Related]
18. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option?
Kahan NR; Chinitz DP; Waitman DA; Dushnitzky D; Kahan E; Shapiro M
Ann Pharmacother; 2006 Dec; 40(12):2223-7. PubMed ID: 17105833
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.
Borsari AG; Bucher B; Brazzola P; Simonetti GD; Dolina M; Bianchetti MG
Clin Ther; 2008 Nov; 30(11):2090-5. PubMed ID: 19108796
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli.
Colodner R; Kometiani I; Chazan B; Raz R
Infection; 2008 Feb; 36(1):41-5. PubMed ID: 18193386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
